connective tissue disease: A disorder characterized by abnormalities in one or more of the elements of the connective tissues, typically associated with genetic defects.
Other localized connective tissue disorders
DOID EFO Endpoint Browser PheWeb
L12_LOCALDCONNECTISSUEOTH
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
682 |
4. Check minimum number of eventsNone |
682 |
5. Include endpoints |
702 |
6. Filter based on genotype QC (FinnGen only) |
702 |
Control definitions (FinnGen only)
- Control exclude
- L12_OTHERSKINSUBCUTIS
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L80-L99
- Name in latin
- Aliae morbositates localisatae textus connectivi
Similar endpoints
↥List of similar endpoints to
Other localized connective tissue disorders
based on the number of shared cases.
Similar with more cases:
- Other disorders of skin and subcutaneous tissue
- Diseases of the skin and subcutaneous tissue
- Any event in hilmo or specialist outpatient
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4269 | 3191 | 1056 |
| Only index persons | 3949 | 2982 | 967 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.08 | 0.09 | 0.03 |
| Only index persons | 0.09 | 0.11 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 53.91 | 55.68 | 48.45 |
| Only index persons | 53.10 | 55.18 | 46.69 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 702 | 557 | 145 |
| Unadjusted period prevalence (%) | 0.16 | 0.19 | 0.06 |
| Median age at first event (years) | 55.86 | 55.95 | 55.55 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 632
- Matched controls
- 6318
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L94.0
ICD-10 Finland
Localized scleroderma [morphea]
+∞
323.0
452
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
15.9
142.4
253
254
L94.9
ICD-10 Finland
Localized connective tissue disorder, unspecified
+∞
62.5
59
*
L94.8
ICD-10 Finland
Other specified localized connective tissue disorders
+∞
52.9
50
*
L94.2
ICD-10 Finland
Calcinosis cutis
+∞
52.9
50
*
D07AD01
ATC
clobetasol; topical
4.6
47.6
194
554
D07AC01
ATC
betamethasone; topical
3.5
47.5
328
1484
M34.9
ICD-10 Finland
Systemic sclerosis, unspecified
99.1
42.4
46
5
D07AC13
ATC
mometasone; topical
3.4
42.2
275
1159
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
31.6
41.6
55
19
L90.0
ICD-10 Finland
Lichen sclerosus et atrophicus
26.0
40.9
57
24
L30.9
ICD-10 Finland
Dermatitis, unspecified
3.8
38.9
195
657
E0000UV
ATC
NA
3.0
37.5
339
1758
P01BA02
ATC
hydroxychloroquine; oral
5.1
36.8
127
296
L94.1
ICD-10 Finland
Linear scleroderma
+∞
35.8
34
*
L98.4
ICD-10 Finland
Chronic ulcer of skin, not elsewhere classified
40.8
33.8
42
11
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
4.7
33.0
123
309
M34.1
ICD-10 Finland
CR(E)ST syndrome
49.6
27.7
33
7
70100
ICD-8 Finland
Other hypertrophic and atrophic conditions of the skin, Seleroderma circumscriptum NUD
+∞
25.2
24
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
3.6
23.7
118
379
L95.9
ICD-10 Finland
Vasculitis limited to skin, unspecified
+∞
22.0
21
*
H02AB06
ATC
prednisolone; systemic
2.3
21.9
335
2088
E000001
ATC
NA
2.7
21.4
173
772
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.3
21.3
301
1800
M34.0
ICD-10 Finland
Progressive systemic sclerosis
62.2
21.0
24
*
XQ848
NOMESCO Finland
Dermatological photography
9.1
19.9
42
49
R21
ICD-10 Finland
Rash and other nonspecific skin eruption
5.4
19.7
61
123
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
4.2
19.4
76
197
XX9XE
NOMESCO Finland
Other ultrasound examination
12.8
18.8
33
27
L04AA01
ATC
[U] ciclosporin; systemic
11.5
18.4
34
31
L04AA06
ATC
mycophenolic acid; systemic
9.3
17.9
37
42
L04AX01
ATC
azathioprine; systemic
5.2
17.7
56
116
C08CA05
ATC
nifedipine; systemic
4.0
17.7
73
198
QDG20
NOMESCO Finland
Operation for chronic ulcer or fistula of skin of lower limb
32.5
17.1
22
7
D07AB08
ATC
desonide; topical
3.2
17.1
99
350
D02AE01
ATC
carbamide; topical
4.0
17.0
71
195
M34.8
ICD-10 Finland
Other forms of systemic sclerosis
65.2
16.8
19
*
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
3.4
16.5
85
277
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.2
16.3
210
1165
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
5.2
15.6
49
101
A46
ICD-10 Finland
Erysipelas
2.9
15.3
98
371
TQW80
NOMESCO Finland
Local dermatologic skincare
7.1
15.2
37
55
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
9.8
15.1
30
32
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
8.9
14.4
30
35
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
22.9
14.3
20
9
D02AX
ATC
Other emollients and protectives
5.5
13.9
41
79
L98.9
ICD-10 Finland
Disorder of skin and subcutaneous tissue, unspecified
34.9
13.6
17
5
L92.0
ICD-10 Finland
Granuloma annulare
143.0
13.5
14
*
L93.0
ICD-10 Finland
Discoid lupus erythematosus
143.0
13.5
14
*
TK800
NOMESCO Finland
Hemodialysis
8.4
13.4
29
36
I73.0
ICD-10 Finland
Raynaud syndrome
7.5
13.4
31
43
J01FF01
ATC
clindamycin; systemic
2.1
13.2
186
1055
L04AD01
ATC
ciclosporin; systemic
9.0
13.1
27
31
190
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
14.4
12.8
21
15
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
3.2
12.7
69
234
XQ841
NOMESCO Finland
Examination of dermatosis with microscope
32.8
12.6
16
5
127
Kela drug reimbursment
Transplant complication
11.3
12.6
23
21
D07AB02
ATC
hydrocortisone butyrate; topical
2.0
12.4
197
1169
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
3.8
12.3
53
150
S97
ICPC
Chronic ulcer skin
4.0
11.4
45
118
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
12.1
11.4
20
17
QDB05
NOMESCO Finland
Revision of wound of skin of lower limb
7.5
11.3
26
36
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.8
11.1
72
274
Z49.1
ICD-10 Finland
Extracorporeal dialysis
10.8
10.8
20
19
C03CA01
ATC
furosemide; systemic
2.0
10.7
164
952
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
2.8
10.6
72
280
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
7.0
10.5
25
37
L95.8
ICD-10 Finland
Other vasculitis limited to skin
111.8
10.4
11
*
M34
ICD-10 Finland
Systemic sclerosis
111.8
10.4
11
*
L95.0
ICD-10 Finland
Livedoid vasculitis
+∞
10.4
10
*
L94.3
ICD-10 Finland
Sclerodactyly
+∞
10.4
10
*
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
2.8
10.3
68
262
XPX04
NOMESCO Finland
Angioscopy
19.2
10.3
15
8
I83.0
ICD-10 Finland
Varicose veins of lower extremities with ulcer
7.7
10.3
23
31
M13.9
ICD-10 Finland
Arthritis, unspecified
3.0
10.2
59
209
D05AX02
ATC
calcipotriol; topical
4.7
10.2
34
76
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.8
10.1
239
1605
S18
ICPC
Laceration/cut
1.8
10.0
259
1790
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
4.1
10.0
38
97
E000006
ATC
NA
2.9
9.9
61
224
E000007
ATC
NA
3.2
9.6
50
165
SPAT1262
SPAT
Handing over of treatment supplies
2.1
9.6
115
603
V03AE02
ATC
sevelamer; oral
17.9
9.4
14
8
N03AX16
ATC
pregabalin; oral
1.9
9.4
159
952
H02AB04
ATC
methylprednisolone; systemic
2.2
9.3
105
533
A12AA04
ATC
calcium carbonate; oral
7.5
9.3
21
29
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.3
9.3
87
406
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
2.8
9.1
60
230
196
Kela drug reimbursment
Paricalcitol and cinacalcet
15.9
9.1
14
9
A11CC03
ATC
alfacalcidol; systemic
5.6
9.0
25
46
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
3.7
8.9
38
108
M04AA01
ATC
allopurinol; systemic
2.5
8.8
71
306
E000002
ATC
NA
2.2
8.7
89
434
V03AE01
ATC
polystyrene sulfonate; oral
10.2
8.6
16
16
NH3DA
NOMESCO Finland
Bilateral foot X-ray examination
5.0
8.5
26
54
N18.0
ICD-10 Finland
End-stage renal disease
13.0
8.4
14
11
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
1.9
8.4
148
896
WXQ10
NOMESCO Finland
Psoralen - Ultraviolet A therapy with systemic sensitivisation
+∞
8.3
8
*
7101A
ICD-9 Finland
Diffuse diseases of connective tissue, Systemic sclerosis[SCLERODERMA]
+∞
8.3
8
*
N18.8
ICD-10 Finland
Other chronic renal failure
5.3
8.2
24
47
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
3.4
8.2
38
116
NHQ40
NOMESCO Finland
Amputation of toe
11.9
8.1
14
12
L89
ICD-10 Finland
Decubitus ulcer and pressure area
33.8
8.1
10
*
E03.9
ICD-10 Finland
Hypothyroidism, unspecified
2.1
8.1
91
464
M25.5
ICD-10 Finland
Pain in joint
1.7
8.0
190
1263
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
2.9
8.0
46
164
E000003
ATC
NA
3.3
8.0
38
119
J01MA02
ATC
ciprofloxacin; systemic
1.7
7.9
225
1570
E10.2
ICD-10 Finland
Type 1 diabetes mellitus, With renal complications
11.0
7.8
14
13
M32.0
ICD-10 Finland
Drug-induced systemic lupus erythematosus
45.5
7.7
9
*
WXQ12
NOMESCO Finland
Psoralen - Ultraviolet A therapy with local sensitivisation
18.6
7.6
11
6
R06AE07
ATC
cetirizine; oral
1.6
7.6
287
2156
Z94.0
ICD-10 Finland
Kidney transplant status
10.2
7.6
14
14
137
Kela drug reimbursment
Uraemia requiring dialysis
10.2
7.6
14
14
TPH30
NOMESCO Finland
Insertion of central venous catheter through periferal vein
7.2
7.5
17
24
QBA99
NOMESCO Finland
Other local destruction of skin of trunk
13.6
7.4
12
9
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
2.6
7.4
52
211
L94
ICD-10 Finland
Other localized connective tissue disorders
+∞
7.3
7
*
TQW11
NOMESCO Finland
Vacuum treatment of wound
6.4
7.3
18
29
320
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
16.0
7.2
11
7
ND2DA
NOMESCO Finland
Bilateral hand X-ray examination
4.8
7.1
22
47
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
10.2
7.1
13
13
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.0
6.9
86
453
I10
ICD-10 Finland
Essential (primary) hypertension
1.6
6.9
322
2531
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
8.4
6.9
14
17
R4120
NOMESCO Finland
Occupational therapy
2.7
6.8
45
176
L04AD02
ATC
tacrolimus; systemic (calcineurin inhibitors)
9.5
6.8
13
14
RJ411
NOMESCO Finland
NA
40.5
6.8
8
*
NHQ30
NOMESCO Finland
Amputation of foot, transmetatarsal
40.5
6.8
8
*
QXA05
NOMESCO Finland
Skin division, unspecified location
40.5
6.8
8
*
B03XA03
ATC
methoxy polyethylene glycol-epoetin beta; parenteral
22.8
6.7
9
*
PF1AT
NOMESCO Finland
Intravascular dilatation of arteries of knee, lower leg and ankle (PTA)
22.8
6.7
9
*
R4110
NOMESCO Finland
Physiotherapy
1.7
6.7
164
1089
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
4.1
6.7
24
60
J01DB01
ATC
cefalexin; oral
1.7
6.6
505
4446
R06AX27
ATC
desloratadine; oral
1.7
6.6
179
1219
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
3.0
6.6
36
125
A02BC02
ATC
pantoprazole; systemic
1.6
6.6
395
3271
H02AB07
ATC
prednisone; oral
1.9
6.6
97
548
J01DA01
ATC
[U] cefalexin; systemic
1.5
6.6
375
3073
QDA10
NOMESCO Finland
Incision of skin of lower limb
10.2
6.6
12
12
H04.10
ICD-10 Finland
Dry eye syndrome
2.1
6.5
71
354
QAA25
NOMESCO Finland
Destruction of lesion of head or neck
5.8
6.5
17
30
NG4AA
NOMESCO Finland
Lower leg X-ray examination
4.0
6.4
24
62
E10.5
ICD-10 Finland
Type 1 diabetes mellitus, With peripheral circulatory complications
70.5
6.4
7
*
G73.7*M34.8
ICD-10 Finland
Myopathy in scleroderma
70.5
6.4
7
*
N08.39*E10.2
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic nephropathy
14.5
6.4
10
7
L91.0
ICD-10 Finland
Hypertrophic scar
14.5
6.4
10
7
E10.7
ICD-10 Finland
Type 1 diabetes mellitus, With multiple complications
5.3
6.4
18
35
S99
ICPC
Skin disease other
5.3
6.4
18
35
RJ412
NOMESCO Finland
NA
+∞
6.3
6
*
L94.4
ICD-10 Finland
Gottron papules
+∞
6.3
6
*
7100A
ICD-9 Finland
Diffuse diseases of connective tissue, Systemic lupus erythematosus
+∞
6.3
6
*
L84
ICD-10 Finland
Corns and callosities
4.2
6.3
22
54
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
2.8
6.2
38
143
L71.8
ICD-10 Finland
Other rosacea
5.8
6.2
16
28
A10AC01
ATC
insulin (human); parenteral (insulins and analog. for injection, intermediate-acting)
2.6
6.2
44
180
N02AX02
ATC
tramadol; systemic, rectal
1.5
6.1
244
1828
N08.39*E11.2
ICD-10 Finland
Non-insulin-dependent diabetes mellitus - Diabetic nephropathy
8.7
6.1
12
14
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
1.8
6.1
98
572
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
128
124
12.40
119.37
1.3
1.2
16.1
10.8
u/ml
—
9
9
157
212
9.25
114.51
1.4
1.3
0.4
1.8
u/ml
—
8
16
124
169
8.70
88.86
1.4
1.2
61.2
22.7
u/ml
—
10
8
120
159
8.90
87.98
1.4
1.2
10.5
2.7
u/ml
0.99
17
18
120
161
8.78
87.06
1.4
1.2
8.6
7.0
u/ml
0.10
21
27
95
127
8.49
68.65
1.4
1.2
25.8
45.6
u/ml
—
10
11
108
192
6.47
59.97
2.6
1.8
—
—
—
0
0
463
2757
3.00
41.58
10.0
5.6
28.3
28.4
%
0.08
447
2556
523
3358
3.19
40.42
11.5
8.8
3.9
4.0
e9/l
0.78
485
2932
46
51
9.58
38.13
1.2
1.2
—
—
—
0
0
46
51
9.58
38.13
1.2
1.2
—
—
—
0
0
46
52
9.40
37.57
1.3
1.2
—
—
—
0
0
46
52
9.40
37.57
1.3
1.2
—
—
—
0
0
46
52
9.40
37.57
1.3
1.2
—
—
—
0
0
126
406
3.56
32.74
2.4
2.4
23.1
18.4
au/ml
—
6
12
34
37
9.61
28.47
1.7
1.4
5.3
8.1
u/l
0.73
26
32
262
1435
2.32
23.93
3.5
2.4
916.1
7028.3
umol/l
4.45
232
1233
288
1683
2.21
22.10
3.1
2.0
159.3
209.0
u/l
0.49
275
1592
162
756
2.49
20.87
4.1
2.1
2.3
2.4
g/l
1.23
146
690
171
822
2.43
20.62
4.1
2.1
12.6
13.0
umol/l
0.32
160
743
568
4418
2.50
20.48
7.0
4.0
14.3
12.1
mm/h
2.64
540
4061
150
697
2.47
19.38
4.2
2.1
22.2
22.5
%
0.10
129
590
63
181
3.73
19.14
1.9
1.5
410.0
143.6
titre
—
8
11
20
18
11.41
18.95
1.4
1.2
9.0
9.1
ug/l
0.03
20
18
377
2555
2.03
18.52
3.1
2.3
77.3
78.2
nmol/l
0.27
339
2277
106
428
2.74
18.20
3.2
2.9
65.8
67.2
g/l
0.83
96
384
570
4527
2.38
18.13
10.4
6.8
77.6
77.2
u/l
0.09
548
4224
143
696
2.32
16.44
13.6
4.0
1.1
1.0
mmol/l
2.10
138
633
370
2576
1.92
15.93
3.9
2.7
107.5
98.3
ug/l
0.64
345
2353
100
425
2.58
15.41
4.2
2.9
308.0
181.3
ng/l
0.45
93
388
40
97
4.31
15.30
1.3
1.2
—
—
—
0
0
396
2852
1.89
15.04
12.8
6.1
1.2
1.2
mmol/l
0.59
333
2401
38
90
4.41
14.97
1.4
1.1
2.3
1.7
u/ml
0.50
17
31
186
1076
1.99
13.45
1.4
1.3
15.5
31.6
iu/ml
3.98
53
348
225
1390
1.91
13.40
2.8
2.1
3.0
3.1
mg/l
0.10
198
1167
35
85
4.28
13.36
1.4
1.2
3.7
3.5
u/ml
0.04
18
38
393
2899
1.81
13.07
4.2
3.6
0.0
0.0
estimate
0.00
76
544
243
1560
1.85
12.72
3.4
2.8
2025.4
1052.5
ng/l
0.84
206
1299
193
1162
1.91
12.26
3.1
2.3
5.4
7.2
e6/l
1.06
167
1028
90
406
2.40
12.13
19.4
5.2
11.9
8.8
mmol/l
3.84
84
384
237
1532
1.83
11.99
3.9
2.8
0.3
0.4
e6/l
1.78
174
1130
389
2912
1.75
11.82
5.7
4.9
0.0
0.0
estimate
0.50
79
545
288
1982
1.77
11.75
4.9
2.9
—
—
—
0
0
355
2603
1.74
11.50
11.6
5.3
1.2
1.2
mmol/l
0.62
325
2354
391
2952
1.73
11.34
4.2
3.7
0.0
0.0
estimate
0.50
80
531
489
3934
1.80
11.33
5.7
4.5
14.6
1335.0
e6/l
—
9
59
51
181
2.96
11.04
3.1
2.4
1.9
0.9
g/l
0.60
46
163
288
2015
1.73
10.86
3.5
3.2
2.4
2.4
mmol/l
0.33
263
1749
53
197
2.83
10.56
2.8
2.1
3.1
3.1
g/l
0.02
44
161
149
863
1.92
10.47
2.1
1.7
—
—
—
0
0
102
519
2.13
10.26
2.3
1.8
326.3
382.0
nmol/l
2.06
96
479
333
2450
1.68
10.25
7.2
4.0
35.3
35.8
g/l
0.76
314
2282
54
208
2.73
10.07
2.8
2.1
3.5
3.7
g/l
0.36
43
159
96
481
2.15
10.04
8.4
3.1
136.6
75.2
ng/l
4.30
88
429
54
209
2.72
9.97
2.8
2.1
7.2
7.5
g/l
0.55
44
166
54
209
2.72
9.97
2.8
2.1
—
—
—
0
0
389
2997
1.67
9.91
6.5
5.6
10.2
10.6
umol/l
0.51
366
2836
35
106
3.42
9.84
3.3
3.2
55.9
57.1
%
0.21
35
106
34
102
3.45
9.70
3.0
3.0
3.8
4.1
e9/l
0.46
34
102
31
88
3.64
9.60
1.4
1.3
—
—
—
0
0
317
2335
1.65
9.49
2.3
1.9
97.6
96.4
pmol/l
0.17
165
1132
152
917
1.84
9.32
3.2
2.5
0.7
1.2
e6/l
1.54
86
491
166
1040
1.78
8.95
1.4
1.3
9.4
12.4
u/ml
0.26
60
391
50
198
2.64
8.84
2.8
2.1
10.8
10.2
g/l
0.29
45
172
46
175
2.74
8.79
2.8
2.0
36.8
37.9
g/l
0.55
40
153
104
566
1.98
8.68
4.6
3.2
—
—
—
0
0
144
878
1.81
8.47
6.0
2.8
0.8
0.8
mmol/l
1.48
135
819
43
166
2.69
8.00
4.2
3.9
65.6
86.0
mg/l
0.20
34
133
42
162
2.69
7.83
4.1
3.9
1.3
2.3
ratio
—
5
15
78
398
2.08
7.75
1.7
1.4
—
—
—
0
0
413
3349
1.57
7.63
6.9
4.1
6.8
6.6
mmol/l
1.33
395
3091
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
36
130
2.86
7.59
4.6
2.7
0.4
0.4
u/ml
0.05
22
73
549
4769
1.69
7.57
5.1
4.2
14.8
14.8
pmol/l
0.07
511
4331
42
166
2.63
7.48
4.3
3.9
41.9
43.1
mg/l
0.02
34
133
18
41
4.48
7.46
1.8
2.7
—
—
—
0
0
202
1394
1.63
7.46
1.4
1.3
0.7
1.6
u/ml
1.36
46
359
247
1790
1.59
7.44
4.1
3.0
6.8
7.0
mmol/l
0.36
202
1501
37
138
2.77
7.36
1.5
1.3
—
—
—
0
0
194
1337
1.62
7.16
1.7
1.5
21.3
21.8
nmol/l
0.15
169
1124
31
108
2.96
6.98
2.0
1.9
120.1
128.1
g/l
1.33
15
75
42
172
2.53
6.98
1.5
1.6
0.1
0.1
iu/ml
—
7
30
61
295
2.17
6.96
4.7
2.9
1.8
2.1
mmol/l
0.22
42
224
88
491
1.91
6.79
2.7
2.0
0.2
0.2
g/l
0.41
80
463
53
246
2.25
6.69
1.8
2.0
37.1
40.4
u/l
0.43
48
214
38
152
2.59
6.63
1.4
1.3
—
—
—
0
0
25
79
3.24
6.62
13.7
3.6
2052.7
633.4
iu/ml
—
6
7
89
503
1.88
6.61
3.1
2.2
27.8
37.3
u/l
1.67
75
421
34
130
2.70
6.48
4.8
3.2
2.1
1.5
mg/l
1.64
34
119
243
1807
1.53
6.31
3.0
2.4
55.1
56.7
u/l
0.35
222
1657
133
858
1.68
6.29
3.5
2.7
4.5
3.4
e6/l
0.40
69
432
17
43
4.03
6.20
1.3
1.4
—
—
—
0
0
641
5911
1.97
6.14
23.4
12.4
21.5
21.6
mg/l
0.03
549
4589
38
159
2.47
6.06
1.9
2.0
9.9
11.5
mg/l
0.45
33
145
14
31
4.59
6.00
1.2
1.1
1.0
1.1
ratio
—
5
10
18
49
3.74
5.95
1.9
1.6
—
—
—
0
0
234
1745
1.51
5.93
5.0
3.9
19.1
8.4
mg/mmol
1.24
146
1031
45
206
2.27
5.89
2.3
1.7
—
—
—
0
0
99
601
1.75
5.81
1.9
1.7
—
—
—
0
0
100
610
1.75
5.77
2.0
1.7
—
—
—
0
0
42
189
2.30
5.72
1.8
1.7
—
—
—
0
0
10
17
5.95
5.64
2.1
1.7
—
—
—
0
0
10
17
5.95
5.64
2.1
1.7
—
—
—
0
0
35
146
2.47
5.63
2.5
2.6
—
—
—
0
0
612
5601
1.72
5.50
6.2
5.0
1.9
1.9
mu/l
0.59
571
5110
669
6305
2.30
5.41
16.3
9.7
25.4
24.9
u/l
0.43
648
6072
35
149
2.42
5.40
1.5
1.1
—
—
—
0
0
81
474
1.80
5.38
8.4
3.1
1.9
2.2
mmol/l
0.24
71
373
10
18
5.62
5.33
2.1
1.7
—
—
—
0
0
58
306
1.98
5.29
1.6
1.6
—
—
—
0
0
31
127
2.51
5.19
1.9
1.4
—
—
—
0
0
14
35
4.06
5.19
1.4
1.9
509.7
513.2
e6/l
—
9
27
14
35
4.06
5.19
1.3
1.2
—
—
—
0
0
152
1059
1.56
5.18
5.1
3.6
69.5
327.9
ng/l
2.74
122
798
25
92
2.78
5.15
2.0
1.5
—
—
—
0
0
608
5576
1.68
5.15
19.3
11.8
80.1
81.7
ml/min/173m2
0.91
533
4479
24
87
2.82
5.09
1.2
1.1
—
—
—
0
0
18
55
3.33
5.05
1.9
1.5
—
—
—
0
0
32
135
2.44
5.05
2.3
1.6
—
—
—
0
0
30
123
2.50
5.02
1.9
1.5
—
—
—
0
0
30
126
2.44
4.79
1.9
1.6
12644.1
18796.6
e6/l
0.37
21
85
651
6110
1.90
4.77
25.1
14.2
4.0
3.9
mmol/l
0.08
634
5925
649
6092
1.87
4.65
24.6
14.1
139.5
139.7
mmol/l
0.74
632
5924
145
1031
1.51
4.46
1.8
1.7
1219.8
1203.7
nmol/l
0.06
116
758
439
3816
1.40
4.41
3.9
2.9
56.7
43.7
u/l
1.36
411
3551
13
35
3.77
4.38
1.5
1.9
843.6
810.5
e6/l
—
5
15
205
1571
1.43
4.29
4.7
4.0
0.0
0.0
estimate
0.69
81
538
13
36
3.66
4.22
1.8
1.8
14.0
13.1
%
—
7
16
24
97
2.53
4.17
1.9
1.6
—
—
—
0
0
19
69
2.80
4.05
1.3
1.3
—
—
—
0
0
19
69
2.80
4.05
1.3
1.3
—
—
—
0
0
20
75
2.72
4.02
1.7
1.4
—
—
—
0
0
9
14
6.50
3.99
1.1
1.3
—
—
—
0
0
19
70
2.76
3.95
1.3
1.3
—
—
—
0
0
19
70
2.76
3.95
1.3
1.3
—
—
—
0
0
63
377
1.74
3.91
1.4
1.2
509.6
232.6
u/ml
0.44
55
344
152
1119
1.46
3.91
1.4
1.5
—
—
—
0
0
94
625
1.58
3.90
4.6
2.3
5.8
6.9
umol/l
0.52
87
528
10
24
4.21
3.90
1.7
1.8
—
—
—
0
0
10
24
4.21
3.90
1.7
1.8
—
—
—
0
0
19
71
2.72
3.85
1.3
1.3
—
—
—
0
0
19
71
2.72
3.85
1.3
1.3
—
—
—
0
0
19
72
2.68
3.76
1.3
1.4
—
—
—
0
0
233
1863
1.38
3.73
4.2
2.9
28.9
30.7
u/l
0.67
225
1766
209
1643
1.39
3.70
1.8
1.7
1.4
1.4
mmol/l
0.47
167
1397
274
2250
1.36
3.70
4.3
3.8
—
—
—
0
0
326
2752
1.34
3.65
4.8
3.9
—
—
—
0
0
10
26
3.89
3.53
2.1
1.5
—
—
—
0
0
10
26
3.89
3.53
2.1
1.5
—
—
—
0
0
10
26
3.89
3.53
2.1
1.5
—
—
—
0
0
10
26
3.89
3.53
2.1
1.5
—
—
—
0
0
26
121
2.19
3.36
1.5
1.7
—
—
—
0
0
145
1090
1.42
3.30
2.6
2.6
2.5
2.5
mmol/l
0.87
132
954
169
1306
1.39
3.28
2.1
1.6
0.8
1.1
mg/l
1.49
131
981
585
5450
1.44
3.23
7.2
5.5
40.0
39.3
mmol/mol
0.82
550
5054
157
1207
1.39
3.13
1.6
1.7
67669615.7
32157706.1
pmol/l
0.22
133
992
174
1361
1.37
3.12
3.5
2.1
—
—
—
0
0
71
467
1.58
3.10
6.6
3.6
1.2
1.2
mmol/l
0.38
60
404
11
34
3.27
3.07
2.1
1.7
—
—
—
0
0
8
16
5.04
3.05
1.3
1.2
—
—
—
0
0
21
95
2.25
2.92
1.2
1.4
—
—
—
0
0
60
386
1.61
2.89
3.2
3.3
4.5
4.5
pmol/l
0.03
53
344
12
41
2.96
2.87
1.3
1.2
—
—
—
0
0
9
23
3.95
2.78
2.4
1.7
105.0
48.6
ug/l
—
9
23
10
32
3.16
2.65
2.1
1.5
40.0
24.2
u/ml
—
5
5
66
445
1.53
2.62
3.3
2.5
55.2
67.8
ml/min/173m2
1.59
28
186
8
20
4.03
2.57
1.3
1.1
—
—
—
0
0
8
20
4.03
2.57
1.3
1.1
—
—
—
0
0
90
650
1.44
2.55
30.7
23.3
1.3
1.3
inr
0.16
15
89
14
56
2.53
2.54
1.0
1.1
1.5
1.5
g/l
0.02
14
51
22
108
2.07
2.54
2.7
2.4
266.1
64.0
ug/min
0.45
14
67
12
45
2.70
2.46
2.3
1.5
—
—
—
0
0
12
45
2.70
2.46
2.3
1.5
—
—
—
0
0
12
45
2.70
2.46
2.3
1.5
—
—
—
0
0
6
12
5.03
2.40
1.5
1.2
—
—
—
0
0
9
27
3.36
2.40
1.2
1.2
—
—
—
0
0
9
27
3.36
2.40
1.2
1.2
—
—
—
0
0
44
276
1.63
2.38
3.1
2.4
0.2
0.2
e6/l
0.08
44
267
536
5001
1.30
2.32
27.7
15.6
13.9
13.7
%
2.84
527
4893
414
3745
1.26
2.31
3.2
3.1
—
—
—
0
0
14
60
2.36
2.23
1.6
1.5
—
—
—
0
0
12
48
2.53
2.19
3.0
2.2
—
—
—
0
0
678
6598
1.81
2.19
33.3
18.9
132.1
133.8
g/l
2.62
670
6494
612
5840
1.37
2.11
5.0
4.3
4.6
4.8
mmol/l
6.12
571
5402
605
5763
1.36
2.11
5.0
4.5
5.9
5.9
mmol/l
0.21
566
5242
23
124
1.88
2.09
1.3
1.3
—
—
—
0
0
15
69
2.20
2.05
1.3
1.4
—
—
—
0
0
19
97
1.99
2.02
1.3
1.3
—
—
—
0
0
621
5950
1.38
1.99
5.5
4.8
2.6
2.8
mmol/l
5.06
579
5473
15
70
2.17
1.99
1.7
1.5
—
—
—
0
0
588
5589
1.32
1.99
4.3
3.8
1.3
1.3
mmol/l
0.34
547
5103
608
5807
1.35
1.99
4.9
4.3
1.5
1.5
mmol/l
1.94
568
5340
6
16
3.77
1.94
1.2
2.0
—
—
—
0
0
19
99
1.94
1.92
3.3
2.2
14.5
15.8
%
0.89
11
45
17
85
2.02
1.91
1.0
1.0
1.7
1.9
u/ml
—
7
35
17
85
2.02
1.91
1.5
1.2
310.2
216.1
u/ml
0.45
12
47
5
12
4.19
1.82
1.6
1.0
—
—
—
0
0
30
185
1.65
1.78
1.4
1.3
167.7
239.1
miu/ml
0.81
14
86
19
102
1.89
1.77
1.5
1.3
—
—
—
0
0
19
102
1.89
1.77
1.5
1.3
—
—
—
0
0
14
67
2.11
1.77
1.1
1.1
—
—
—
0
0
29
178
1.66
1.75
1.3
1.4
227.2
303.9
ug/g
1.42
18
102
7
24
2.94
1.72
1.0
1.3
—
—
—
0
0
16
82
1.97
1.70
1.3
1.4
—
—
—
0
0
59
429
1.41
1.67
2.3
2.2
26.2
6.1
ug/l
0.65
48
373
17
90
1.91
1.66
1.5
1.2
—
—
—
0
0
7
25
2.82
1.65
2.1
2.7
529.6
1049.1
u/ml
—
7
25
8
32
2.52
1.60
1.3
1.2
—
—
—
0
0
13
64
2.05
1.55
1.4
1.7
40.7
60.5
%
—
7
47
8
33
2.44
1.54
1.6
1.3
2.3
2.1
mmol/l
—
8
33
10
44
2.29
1.53
1.6
1.4
—
—
—
0
0
239
2107
1.20
1.52
3.9
3.3
60.5
34.4
ng/l
0.64
171
1397
14
72
1.96
1.49
1.0
1.0
—
—
—
0
0
153
1294
1.23
1.47
5.1
4.0
1.0
1.0
kg/l
0.19
20
196
61
457
1.37
1.47
1.3
1.2
165.3
163.8
iu/ml
0.01
23
181
15
80
1.89
1.45
1.1
1.1
—
—
—
0
0
37
260
1.45
1.30
1.3
1.3
24.3
29.4
iu/l
0.38
29
218
12
62
1.95
1.28
1.2
1.4
31.1
31.7
pg
0.12
12
62
10
48
2.10
1.28
2.0
1.1
—
—
—
0
0
5
19
2.64
1.22
1.0
1.0
—
—
—
0
0
32
222
1.46
1.21
1.7
2.1
9360.7
4537.5
u/l
0.21
13
99
30
208
1.46
1.14
1.7
1.7
—
—
—
0
0
73
587
1.27
1.11
11.1
7.2
0.7
1.3
mmol/l
0.56
63
472
7
32
2.20
1.08
1.1
1.1
—
—
—
0
0
7
35
2.01
1.00
4.0
1.6
—
—
—
0
0
23
160
1.45
0.90
2.3
1.8
3.6
5.3
iu/l
—
5
52
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
30
2.01
0.87
1.2
1.2
—
—
—
0
0
6
30
2.01
0.87
1.5
1.3
—
—
—
0
0
6
31
1.94
0.84
1.5
1.3
—
—
—
0
0
11
65
1.70
0.82
3.3
2.1
164.3
211.4
pmol/l
0.32
11
60
0
24
0.00
0.79
0.0
2.1
—
41.5
—
0
15
0
24
0.00
0.79
0.0
1.2
—
114.5
—
0
19
26
191
1.38
0.78
1.3
1.1
—
—
—
0
0
26
192
1.37
0.76
1.3
1.1
—
—
—
0
0
5
26
1.93
0.70
1.0
1.2
82.7
156.1
iu/ml
—
5
26
73
622
1.19
0.70
1.5
1.7
1.6
1.4
%
1.12
67
552
50
605
0.81
0.70
2.0
2.0
—
—
—
0
0
554
5386
1.14
0.69
24.8
13.8
39.2
39.5
%
0.32
382
3866
7
42
1.67
0.68
1.0
1.0
—
—
—
0
0
7
42
1.67
0.68
1.1
2.0
—
—
—
0
0
57
479
1.21
0.65
3.0
2.7
0.9
0.7
ug/l
0.33
41
287
5
30
1.67
0.61
2.2
1.3
26.0
31.5
umol/l
—
5
30
33
263
1.27
0.60
18.4
7.6
23.9
24.5
mmol/l
0.47
33
244
0
21
0.00
0.60
0.0
1.2
—
0.3
—
0
15
10
64
1.57
0.59
3.1
3.5
—
—
—
0
0
6
35
1.72
0.57
1.5
1.3
—
—
—
0
0
57
664
0.85
0.56
2.0
2.1
—
—
—
0
0
9
63
1.43
0.52
1.2
1.0
—
—
—
0
0
6
40
1.50
0.51
1.0
1.0
—
—
—
0
0
6
41
1.47
0.50
1.2
1.2
1.1
1.3
nmol/l
—
6
36
20
154
1.31
0.49
2.3
1.7
—
—
—
0
0
7
49
1.43
0.46
1.1
1.4
30438.9
146980.0
e6/l
—
7
31
74
659
1.14
0.45
3.8
4.0
24.9
21.8
%
0.82
41
280
6
94
0.64
0.42
1.0
1.1
—
18.6
—
0
14
0
16
0.00
0.41
0.0
1.0
—
22.9
—
0
16
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
40
343
1.18
0.41
1.7
1.3
—
—
—
0
0
0
17
0.00
0.40
0.0
1.1
—
—
—
0
0
35
297
1.19
0.40
1.5
1.7
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
20
247
0.80
0.38
2.0
1.4
—
—
—
0
0
28
234
1.20
0.38
1.5
1.7
3.1
2.3
mg/l
0.70
23
173
20
246
0.81
0.37
13.4
2.3
1.2
1.2
%
0.04
20
246
37
318
1.17
0.37
1.8
1.5
—
—
—
0
0
6
42
1.43
0.35
1.5
1.3
—
—
—
0
0
17
135
1.27
0.35
1.4
1.2
11.1
9.7
u/l
0.19
12
106
77
701
1.11
0.35
9.2
6.1
—
—
—
0
0
81
740
1.11
0.35
4.6
4.4
33.1
32.9
%
0.06
61
486
12
91
1.32
0.34
1.0
1.1
—
—
—
0
0
6
45
1.34
0.34
1.3
1.2
—
—
—
0
0
6
45
1.34
0.34
1.3
1.2
—
—
—
0
0
27
314
0.85
0.30
1.3
1.5
—
—
—
0
0
15
184
0.81
0.29
1.1
1.5
—
—
—
0
0
18
216
0.83
0.28
1.5
1.4
—
—
—
0
0
14
172
0.81
0.27
1.1
1.4
—
—
—
0
0
18
213
0.84
0.25
2.6
2.8
897.7
801.5
u/ml
0.04
18
180
66
609
1.09
0.25
2.8
3.9
47.6
27.1
ug/l
0.18
52
499
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
8
101
0.79
0.21
2.0
1.5
—
—
—
0
0
29
323
0.89
0.20
1.1
1.0
—
—
—
0
0
6
51
1.18
0.19
1.0
1.1
—
—
—
0
0
25
224
1.12
0.17
1.4
1.4
—
—
—
0
0
15
173
0.86
0.17
1.1
1.4
—
—
—
0
0
15
173
0.86
0.17
1.1
1.4
—
—
—
0
0
15
172
0.87
0.16
1.1
1.4
—
—
—
0
0
8
73
1.10
0.15
1.4
1.3
3.3
2.9
ug/l
—
8
61
126
1223
1.04
0.12
1.6
1.4
—
—
—
0
0
18
163
1.11
0.11
1.4
1.2
—
—
—
0
0
22
239
0.92
0.10
12.3
2.3
0.8
0.7
%
0.86
22
233
6
56
1.07
0.08
1.0
1.1
—
—
—
0
0
42
402
1.05
0.07
2.1
3.6
29.7
51.2
u/ml
1.04
42
388
8
78
1.03
0.07
1.0
1.1
—
—
—
0
0
52
506
1.03
0.04
1.6
1.6
—
—
—
0
0
10
91
1.10
0.04
1.5
1.8
—
—
—
0
0
20
210
0.95
0.03
1.2
1.8
—
—
—
0
0
39
382
1.02
0.01
1.7
1.8
—
—
—
0
0
12
125
0.96
0.00
1.5
1.7
—
—
—
0
0
15
152
0.99
0.00
1.1
1.3
—
—
—
0
0
11
111
0.99
0.00
1.4
1.5
—
—
—
0
0
15
149
1.01
0.00
1.4
1.6
—
—
—
0
0
6
61
0.98
0.00
1.0
1.1
—
—
—
0
0
6
61
0.98
0.00
1.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
2.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
0.6
—
0
8
15
150
1.00
0.00
1.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
6
62
0.97
0.00
3.2
2.0
12.8
13.2
%
—
6
62
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
2.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
6.7
—
0
5
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
44.8
—
0
5
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
6
69
0.87
0.00
2.3
1.9
3.0
65.9
u/ml
—
6
63
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
11.7
—
0
5
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_LOCALDCONNECTISSUEOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_LOCALDCONNECTISSUEOTH | 1.609 [1.39, 1.87] | < 0.001 |
| Birth year | 0.987 [0.98, 1.0] | 0.004 |
During the follow-up period (1.1.1998 — 31.12.2019), 414 out of 2658 females with L12_LOCALDCONNECTISSUEOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_LOCALDCONNECTISSUEOTH | 1.885 [1.5, 2.36] | < 0.001 |
| Birth year | 0.985 [0.98, 0.99] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 166 out of 878 males with L12_LOCALDCONNECTISSUEOTH died.
Mortality risk
Mortality risk for people of age
years, who have L12_LOCALDCONNECTISSUEOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.132% | 0.253% |
| 5 | 0.812% | 1.947% |
| 10 | 1.838% | 5.043% |
| 15 | 3.557% | 9.345% |
| 20 | 6.019% | 15.559% |
Relationships between endpoints
↥Index endpoint: L12_LOCALDCONNECTISSUEOTH – Other localized connective tissue disorders
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data